Clusterin

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

Retrieved on: 
Tuesday, March 28, 2023
Emory University, SPARC, Clusterin, Cognition, Research, Meta-analysis, Biomarker, Publication, Cerebrospinal fluid, Protein, Amyloid, International Conference on Emerging Infectious Diseases, Data, Synapse, CSF, Poster, Patient, AD, Therapy, CLU, Conference, SHINE, Neuroinflammation, Pharmaceutical industry, Vaccine

Treatment with CT1812 was associated with statistically significant and directionally positive effects on key proteins and corresponding Alzheimer’s disease pathways.

Key Points: 
  • Treatment with CT1812 was associated with statistically significant and directionally positive effects on key proteins and corresponding Alzheimer’s disease pathways.
  • These included:
    These robust biomarker findings point towards a prominent effect of CT1812 in altering underlying disease processes active in Alzheimer’s disease progression.
  • The biomarker findings summarized in the poster further strengthen our understanding of CT1812’s effect on Aβ oligomer-driven neurotoxicity.
  • Following the conclusion of the conference, the poster will be made available on our website on the Publications webpage.

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

Retrieved on: 
Thursday, August 4, 2022
Lewy body, U.S. Securities and Exchange Commission, Risk, CEO, Dementia, GLOBE, Brain, SPARC, Security (finance), Research, Patient, Culture Collection (University of Gothenburg), MRI, CLU, Clusterin, CSF, Government budget balance, HIV disease progression rates, GWAS, Inflammation, Hippocampus, Autophagy, Learning, Cognition, Safety, SV2A, Conference, Biomarker, Traffic barrier, Synapse, SHINE, SHIMMER, Therapy, Degenerative disease, Oxidative stress, Private Securities Litigation Reform Act, DLB, Proteomics, AAIC, Memory, Gothenburg, Liver injury, Alzheimer's disease, Central nervous system, NASDAQ, University, Retina, Vance DeGeneres, Pharmaceutical industry, Medical imaging

The analytic results support the proposed synaptoprotective mechanism of action of CT1812 and role in normalizing cellular processes known to be adversely disrupted in Alzheimer's disease .

Key Points: 
  • The analytic results support the proposed synaptoprotective mechanism of action of CT1812 and role in normalizing cellular processes known to be adversely disrupted in Alzheimer's disease .
  • The analyses demonstrated the effect of CT1812 on multiple priority Alzheimers biomarkers, including YKL-40, a biomarker of inflammation, which is upregulated in Alzheimers disease and is subject of intense focus by the field.
  • Participants treated with CT1812 exhibited a downward shift in YKL-40 towards levels observed in healthy, non-demented individuals, supporting a positive impact of CT1812 on disease biology.
  • This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimers disease progression.

Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

Retrieved on: 
Wednesday, July 28, 2021
Cancer, Clusterin, Anti-inflammatory, Branches of biology, Virotherapy, Clusters of differentiation

Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical ingredient in PD-001, the Company's patented oral formulation of cepharanthine. The results from the study validate cepharanthine's potential in treating different types of cancer including esophageal, colorectal, liver and skin. The results also provide confidence in the Company's plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.

Key Points: 
  • Based on the de-risked and positive results from the study, the Company has initiated the following activities:
    Broadening intellectual property strategy with planned filing of provisional patents on cepharanthine for specific cancers.
  • Cepharanthine has been shown in preclinical efficacy models to restore cancer cell sensitivity to multiple unrelated classes of chemotherapy.
  • In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties5.
  • The Company is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases.

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Biology, Neurodegeneration, Neuroscience, Senescence, Alzheimer's disease, Clusterin

Clene was awarded a NAM Catalyst Award based on the novelty and innovation of CNM-Au8 as a therapeutic approach to neuronal aging-related diseases.

Key Points: 
  • Clene was awarded a NAM Catalyst Award based on the novelty and innovation of CNM-Au8 as a therapeutic approach to neuronal aging-related diseases.
  • \xe2\x80\x9cAt Clene, we are dedicated to revolutionizing the treatment of neurodegenerative disease using bioenergetic nanocatalysts.
  • The support from NAM provides an opportunity to potentially expand CNM-Au8\xe2\x80\x99s target indications to additional neurodegenerative diseases of aging, including Alzheimer\xe2\x80\x99s disease.
  • Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting

Retrieved on: 
Friday, March 12, 2021
Oncology, Clusterin, Proteins, Ovarian cancer, AXL receptor tyrosine kinase, Branches of biology, Medical specialties, Clinical medicine

We remain focused on advancing the ongoing pivotal Phase 3 trial of AVB-500 to address the unmet needs of patients with ovarian cancer.

Key Points: 
  • We remain focused on advancing the ongoing pivotal Phase 3 trial of AVB-500 to address the unmet needs of patients with ovarian cancer.
  • For additional information, please visit the Society of Gynecologic Oncology Annual Meeting on Womens Cancer website: www.sgo.org .
  • In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian cancer and clear cell renal cancer.
  • Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg.

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

Retrieved on: 
Monday, March 8, 2021
Kidney cancer, Medical specialties, Clinical medicine, Branches of biology, Clear cell renal cell carcinoma, Renal cell carcinoma, Clusterin, GAS6, Cancer, C-Met, Clear cell carcinoma

The trial will enroll patients with advanced clear cell renal cell carcinoma (ccRCC) that have progressed on front-line treatment.

Key Points: 
  • The trial will enroll patients with advanced clear cell renal cell carcinoma (ccRCC) that have progressed on front-line treatment.
  • Given that there is a large unmet need for effective treatments in renal cell carcinoma, we look forward to advancing the development of AVB-500 to potentially improve outcomes for patients with renal cancer.
  • AXL/GAS6 is associated with poor prognosis and resistance mechanisms in renal cell carcinoma.
  • In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian cancer and clear cell renal cancer.

Second Generation Transitions into Leadership at Thomas Financial

Retrieved on: 
Tuesday, February 2, 2021
Given names, Clusterin, Proteins, CLU, Lauren, Tom Compton

"It has been an honor and a pleasure to lead Thomas Financial these last 45 years," said Rick Thomas.

Key Points: 
  • "It has been an honor and a pleasure to lead Thomas Financial these last 45 years," said Rick Thomas.
  • Rick Thomas, CLU, AEP, founded Thomas Financial in 1975 and has led it to become a leader in creating imaginative and appropriate financial solutions for high net worth individuals and growth companies.
  • Lauren Thomas Compton, CFP, CLU, has been with Thomas Financial since 2004.
  • "Thomas Financial and its team mean the world to me, and I'm honored and excited for the opportunity to lead," said Lauren Thomas Compton.

Major shareholder announcement

Retrieved on: 
Thursday, October 1, 2020
Branches of biology, Clusterin, Proteins, Neurodegeneration, Biology

Copenhagen,Denmark, October 1, 2020 Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notification pursuant to Section 30 of the Danish Capital Markets Act.

Key Points: 
  • Copenhagen,Denmark, October 1, 2020 Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notification pursuant to Section 30 of the Danish Capital Markets Act.
  • Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases.
  • Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland.
  • Thiscompany announcementmay contain certain forward-looking statements, including with respect to the terms, timing and completion of the proposed offering.

MARK MCLENNON NAMED DIRECTOR OF THE CHARTERED LIFE UNDERWRITER® (CLU®) EDUCATION PROGRAM AT THE AMERICAN COLLEGE OF FINANCIAL SERVICES

Retrieved on: 
Monday, June 1, 2020
Programming languages, The American College of Financial Services, CLU, Computer languages, Chfc, Chartered, Clusterin, Personal finance

King of Prussia, PA, June 01, 2020 (GLOBE NEWSWIRE) -- Chad Patrizi, Executive Vice President and Provost at The American College of Financial Services, announced today that Mark McLennon, JD, CLU,ChFC, CFP, PFS/CPA, has been named Director for the Chartered Life Underwriter (CLU) Education Program and Assistant Professor of Business Planning.

Key Points: 
  • King of Prussia, PA, June 01, 2020 (GLOBE NEWSWIRE) -- Chad Patrizi, Executive Vice President and Provost at The American College of Financial Services, announced today that Mark McLennon, JD, CLU,ChFC, CFP, PFS/CPA, has been named Director for the Chartered Life Underwriter (CLU) Education Program and Assistant Professor of Business Planning.
  • For nearly 100 years, the CLU has set the gold standard for life insurance in the financial services profession.
  • McLennon will be responsible for leading the CLU program asT he College continues to modernize the curriculum, including the new Personal Pathway learning model.
  • The American College of Financial Services was founded in 1927 and is the nations largest nonprofit educational institution devoted to financial services.

MARK MCLENNON NAMED DIRECTOR OF THE CHARTERED LIFE UNDERWRITER® (CLU®) EDUCATION PROGRAM AT THE AMERICAN COLLEGE OF FINANCIAL SERVICES

Retrieved on: 
Monday, June 1, 2020
The American College of Financial Services, CLU, Chartered, Chfc, Clusterin, Personal finance, Professional certification in finance

King of Prussia, PA, June 01, 2020 (GLOBE NEWSWIRE) -- June 1, 2020 Chad Patrizi, Executive Vice President and Provost at The American College of Financial Services, announced today that Mark McLennon, JD, CLU, ChFC, CFP, PFS/CPA, has been named Director for the Chartered Life Underwriter (CLU) Education Program and Assistant Professor of Business Planning.

Key Points: 
  • King of Prussia, PA, June 01, 2020 (GLOBE NEWSWIRE) -- June 1, 2020 Chad Patrizi, Executive Vice President and Provost at The American College of Financial Services, announced today that Mark McLennon, JD, CLU, ChFC, CFP, PFS/CPA, has been named Director for the Chartered Life Underwriter (CLU) Education Program and Assistant Professor of Business Planning.
  • For nearly 100 years, the CLU has set the gold standard for life insurance in the financial services profession.
  • McLennon will be responsible for leading the CLU program as The College continues to modernize the curriculum, including the new Personal Pathway learning model.
  • ### ABOUT THE AMERICAN COLLEGE OF FINANCIAL SERVICES The American College of Financial Services was founded in 1927 and is the nations largest nonprofit educational institution devoted to financial services.